CIGEX
Price
$21.96
Change
+$0.09 (+0.41%)
Updated
Jun 22 closing price
Net Assets
204.55M
RNPAX
Price
$68.33
Change
-$0.10 (-0.15%)
Updated
Jun 22 closing price
Net Assets
171.51B
Interact to see
Advertisement

CIGEX vs RNPAX

CIGEX vs RNPAX Comparison Chart in %
View a ticker or compare two or three
VS
CIGEX vs. RNPAX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CIGEX is a Buy and RNPAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RNPAX has more cash in the bank: 172B vs. CIGEX (205M). RNPAX pays higher dividends than CIGEX: RNPAX (0.36) vs CIGEX (0.00). CIGEX was incepted earlier than RNPAX: CIGEX (19 years) vs RNPAX (24 years). RNPAX (1.49) is less costly to investors than CIGEX (1.25). CIGEX is a more actively managed with annual turnover of: 114.00 vs. RNPAX (23.00). RNPAX has a lower initial minimum investment than CIGEX: RNPAX (250) vs CIGEX (1000000). CIGEX annual gain was more profitable for investors over the last year : 17.83 vs. RNPAX (11.98). CIGEX return over 5 years is better than : 23.12 vs. RNPAX (10.66).
CIGEXRNPAXCIGEX / RNPAX
Total Expense Ratio1.151.4977%
Annual Report Gross Expense Ratio1.251.4984%
Fund Existence19 years24 years-
Gain YTD21.6356.070356%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets205M172B0%
Annual Yield % from dividends0.000.36-
Returns for 1 year17.8311.98149%
Returns for 3 years64.1037.06173%
Returns for 5 years23.1210.66217%
Returns for 10 years82.77109.7875%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ETHT9.140.28
+3.16%
Proshares Ultra Ether ETF
SEMI40.720.14
+0.34%
Columbia Select Technology ETF
IMRA17.23N/A
N/A
Bitwise MARA Option Income Strategy ETF
JSI51.27-0.07
-0.14%
Janus Henderson Securitized Income ETF
BTAL10.92-0.04
-0.36%
AGF U.S. Market Neutral Anti-Beta